Oncolytics kicks off reovirus trial

Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.

Related Content:

Oncology NEWS International Vol 18 No 3

Genetics opens new window on acute myeloid leukemia

Pralatrexate: Upfront Rx strategy for T-cell lymphoma

Who's News